OpGen

OpGen ROCE

The Return on Capital Employed (ROCE) of OpGen (OPGN) as of Oct 20, 2026 is 75.43 %. In the previous year, Return on Capital Employed (ROCE) was 5.42 % — a change of 1,292.23% (higher).

ROCE

75.43 %

YoY

1,292.23%

Last updated:

In 2025, OpGen's return on capital employed (ROCE) was 75.43 %, a 1,292.23% increase from the 5.42 % ROCE in the previous year.

The OpGen ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-398.34 USD
Jan 1, 2019
-285.81 USD
Jan 1, 2020
-101.43 USD
Jan 1, 2021
-56.46 USD
Jan 1, 2022
-293.28 USD
Jan 1, 2023
135.69 USD
Jan 1, 2024
5.42 USD
Jan 1, 2025
75.43 USD
The OpGen ROCE history
YEARROCEYoY
75.43 %+1,292.23%
5.42 %-96.01%
135.69 %-146.27%
-293.28 %+419.41%
-56.46 %-44.33%
-101.43 %-64.51%
-285.81 %-28.25%
-398.34 %-63.38%
-1,087.75 %+81.25%
-600.14 %+209.34%
-194.00 %-381.18%
69.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling OpGen's Return on Capital Employed (ROCE)

OpGen's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing OpGen's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

OpGen's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in OpGen’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about OpGen stock

Return on Capital Employed (ROCE) of OpGen is 75.43 % in 2025.

Return on Capital Employed (ROCE) of OpGen changed from 5.42 % to 75.43 %, representing a 1,292.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) OpGen since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s OpGen with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — OpGen

All Key Metrics — OpGen